Epoch Investment Partners Inc. Makes New Investment in Gilead Sciences, Inc. $GILD

Key Points

• Epoch Investment Partners Inc. has acquired a new position in Gilead Sciences, purchasing 115,039 shares valued at approximately $12.89 million.
• Gilead announced a quarterly dividend of $0.79, set to be paid to stockholders on September 29th, representing an annualized dividend yield of 2.8%.
• The company's recent earnings report showed a quarterly revenue of $7.08 billion, exceeding analyst expectations and reflecting a 1.4% year-over-year increase.

Epoch Investment Partners Inc. bought a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 115,039 shares of the biopharmaceutical company's stock, valued at approximately $12,890,000.

Several other institutional investors and hedge funds have also modified their holdings of GILD. Brighton Jones LLC increased its stake in shares of Gilead Sciences by 20.6% in the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company's stock valued at $1,326,000 after buying an additional 2,450 shares during the period. Nebula Research & Development LLC bought a new stake in Gilead Sciences during the 4th quarter worth approximately $288,000. Two Sigma Securities LLC increased its position in Gilead Sciences by 164.4% in the 4th quarter. Two Sigma Securities LLC now owns 2,253 shares of the biopharmaceutical company's stock valued at $208,000 after acquiring an additional 5,753 shares during the period. Lido Advisors LLC raised its stake in shares of Gilead Sciences by 7.9% during the fourth quarter. Lido Advisors LLC now owns 63,754 shares of the biopharmaceutical company's stock valued at $5,889,000 after acquiring an additional 4,680 shares during the last quarter. Finally, Utah Retirement Systems raised its stake in shares of Gilead Sciences by 0.3% during the fourth quarter. Utah Retirement Systems now owns 207,051 shares of the biopharmaceutical company's stock valued at $19,125,000 after acquiring an additional 600 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $118.53, for a total transaction of $3,318,840.00. Following the transaction, the insider owned 114,168 shares of the company's stock, valued at $13,532,333.04. The trade was a 19.70% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Daniel Patrick O'day sold 10,000 shares of the company's stock in a transaction on Monday, July 28th. The stock was sold at an average price of $113.94, for a total value of $1,139,400.00. Following the sale, the chief executive officer owned 605,725 shares of the company's stock, valued at $69,016,306.50. This trade represents a 1.62% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 82,000 shares of company stock worth $9,371,330 over the last three months. Company insiders own 0.27% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on GILD shares. Royal Bank Of Canada upped their price objective on shares of Gilead Sciences from $96.00 to $98.00 and gave the company a "sector perform" rating in a research note on Friday, August 8th. Daiwa America upgraded Gilead Sciences from a "hold" rating to a "strong-buy" rating in a report on Tuesday, August 19th. Daiwa Capital Markets raised Gilead Sciences from a "neutral" rating to an "outperform" rating and set a $128.00 price objective on the stock in a research note on Tuesday, August 19th. UBS Group upped their target price on Gilead Sciences from $108.00 to $112.00 and gave the company a "neutral" rating in a research report on Friday, August 8th. Finally, Truist Financial upgraded Gilead Sciences from a "hold" rating to a "buy" rating and lifted their target price for the stock from $108.00 to $127.00 in a report on Friday, August 8th. Three analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $115.39.

Gilead Sciences Stock Up 0.4%

Gilead Sciences stock traded up $0.41 during mid-day trading on Monday, reaching $112.97. The stock had a trading volume of 4,629,720 shares, compared to its average volume of 6,308,101. The firm has a market capitalization of $140.17 billion, a PE ratio of 22.50, a price-to-earnings-growth ratio of 0.70 and a beta of 0.36. Gilead Sciences, Inc. has a fifty-two week low of $77.74 and a fifty-two week high of $121.83. The stock's 50-day simple moving average is $113.01 and its 200-day simple moving average is $109.66. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.96 by $0.05. The company had revenue of $7.08 billion for the quarter, compared to analysts' expectations of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.Gilead Sciences's quarterly revenue was up 1.4% compared to the same quarter last year. During the same period last year, the business earned $2.01 EPS. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, sell-side analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, September 29th. Shareholders of record on Monday, September 15th will be issued a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date of this dividend is Monday, September 15th. Gilead Sciences's payout ratio is currently 62.95%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.